Author pages are created from data sourced from our academic publisher partnerships and public sources.
The diagnostic criteria for multiple sclerosis: From Charcot to McDonald.
The history of diagnostic criteria for multiple sclerosis (MS) from Charcot to McDonald is reviewed. Although the criteria have evolved positively with each revision we think there is still room for… Expand
Remote Monitoring in the Home Validates Clinical Gait Measures for Multiple Sclerosis
- Akara Supratak, G. Datta, A. Gafson, R. Nicholas, Y. Guo, P. Matthews
- Front. Neurol.
- 13 July 2018
Background: The timed 25-foot walk (T25FW) is widely used as a clinic performance measure, but has yet to be directly validated against gait speed in the home environment. Objectives: To develop an… Expand
Multiple sclerosis therapy and Epstein-Barr virus antibody titres.
- J. Raffel, R. Dobson, A. Gafson, M. Mattoscio, P. Muraro, G. Giovannoni
- Multiple sclerosis and related disorders
- 1 May 2014
BACKGROUND Anti-Epstein-Barr virus (EBV) nuclear antigen-1 (anti-EBNA-1) IgG antibody titres have been found to correlate with MRI and clinical measures of disease activity in MS. Despite being a… Expand
Anti-JC virus antibody titres increase over time with natalizumab treatment
Background: Anti-JC virus antibody status is a risk factor for progressive multifocal leukoencephalopathy after natalizumab treatment in multiple sclerosis. Previous studies have used a… Expand
Lipoprotein markers associated with disability from multiple sclerosis
- A. Gafson, T. Thorne, C. I. J. McKechnie, B. Jiménez, R. Nicholas, P. Matthews
- Scientific Reports
- 2 November 2018
Altered lipid metabolism is a feature of chronic inflammatory disorders. Increased plasma lipids and lipoproteins have been associated with multiple sclerosis (MS) disease activity. Our objective was… Expand
Neurofilaments: neurobiological foundations for biomarker applications.
- A. Gafson, Nicolas R. Barthélemy, +9 authors P. Matthews
- Biology, Medicine
- Brain : a journal of neurology
- 14 May 2020
Interest in neurofilaments has risen sharply in recent years with recognition of their potential as biomarkers of brain injury or neurodegeneration in CSF and blood. This is in the context of a… Expand
Personalised medicine for multiple sclerosis care
Treatments with a range of efficacy and risk of adverse events have become available for the management of multiple sclerosis (MS). However, now the heterogeneity of clinical expression and responses… Expand
Towards the incorporation of lumbar puncture into clinical trials for multiple sclerosis
Multiple Sclerosis (MS) is the commonest disabling condition to affect young people resulting in long-term cumulative disability. Whilst recent years have been characterized by the introduction of… Expand
CCSVI-A. A call to clinicans and scientists to vocalise in an Internet age.
In 2008, Paulo Zamboni pioneered the 'liberation procedure' for treating multiple sclerosis (MS), claiming that MS is caused by an abnormality of venous drainage which he called chronic cerebrospinal… Expand
Breaking the cycle
- A. Gafson, C. Savva, +7 authors P. Matthews
- Chemistry, Medicine
- Neurology: Neuroimmunology & Neuroinflammation
- 22 April 2019
Objective To infer molecular effectors of therapeutic effects and adverse events for dimethyl fumarate (DMF) in patients with relapsing-remitting MS (RRMS) using untargeted plasma metabolomics.… Expand